Discoverpoint-of-care toolslike our insurance coverage checker for CGMs and medications and dosing info for T2D
Home
Admin PortalData Dashboard
RESOURCES ∨
NEWS
EVENTS
FOR MEMBERS ∨
VBR ∨
FOR PATIENTS
QUALITY INITIATIVES ∨
ABOUT ∨

Anti-Obesity Medication Coverage by Payer in Michigan 2023 Quick Reference Guide

Download ResourceLink to Resource
Quickly reference insurance provider coverage of anti-obesity medications, including phentermine, Lomaira (phentermine 8), Qsymia (phentermine-topiramate), Contrave (naltrexone HCI-bupropion HC), Saxenda (liraglutide), and Wegovy (semaglutide).
Providers include private Blue Cross Blue Shield of Michigan, HAP, and Priority Health, as well as public Medicare, Medicare Advantage, and Medicaid coverage.
Developed by the Michigan Collaborative for Type 2 Diabetes, last updated January 1, 2023 with 2023 Q1 formulary information.
Providers, have you used this tool? Give us your feedback to help improve it for others

Tags:

For ProvidersNon-videoPDFMedicarePoint-of-careCreated-By-MCT2D

Subscribe to the MCT2D Newsletter

* indicates required
Blue Cross Blue Shield Blue Care Network of Michigan

Support for the Michigan Collaborative on Type 2 Diabetes is provided by Blue Cross Blue Shield of Michigan and Blue Care Network as part of the BCBSM Value Partnerships program. BCBSM’s Value Partnerships program provides clinical and executive support for all CQI programs. To learn more about Value Partnerships, visit www.valuepartnerships.com. Although Blue Cross Blue Shield of Michigan and the Michigan Collaborative on Type 2 Diabetes work in partnership, the opinions, beliefs, and viewpoints expressed by MCT2D do not necessarily reflect the opinions, beliefs, and viewpoints of BCBSM or any of its employees.

PATIENT STORIESPOINT-OF-CARE-TOOLSSUBMIT A CASE SUMMARYSUBMIT FEEDBACK